Beta lactam antibiotic monotherapy versus beta lactam-aminoglycoside antibiotic combination therapy for sepsis

Paul, Mical; Grozinsky‐Glasberg, Simona; Soares‐Weiser, Karla; Leibovici, Leonard

doi:10.1002/14651858.cd003344.pub2

Cited by 127 publications

(107 citation statements)

References 111 publications

Supporting

Mentioning

103

Contrasting

Unclassified

Order By: Relevance

“…Despite the overall favorable evidence for combination therapy in septic shock, direct evidence from adequately powered RCTs is not available to validate this approach definitively. Nonetheless, in clinical scenarios of severe clinical illness (particularly septic shock), several days of combination therapy is biologically plausible and is likely to be clinically useful [152,167,168] even if evidence has not definitively demonstrated improved clinical outcome in bacteremia and sepsis without shock [174,175]. Thus, we issue a weak recommendation based on low quality of evidence.…”

Section: Combinaɵon Therapymentioning

confidence: 99%

“…Despite evidence suggesting benefit of combination therapy in septic shock, this approach has not been shown to be effective for ongoing treatment of most other serious infections, including bacteremia and sepsis without shock [168,174,175]. The term "ongoing treatment" includes extended empiric therapy for culturenegative infections and extended definitive/targeted therapy where a pathogen is identified.…”

Section: Combinaɵon Therapymentioning

confidence: 99%

See 1 more Smart Citation

Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016

et al. 2017

View full text Add to dashboard Cite

Objective: To provide an update to "Surviving Sepsis Campaign Guidelines for Management of Sepsis and Septic Shock: 2012". Design:A consensus committee of 55 international experts representing 25 international organizations was convened. Nominal groups were assembled at key international meetings (for those committee members attending the conference). A formal conflict-of-interest (COI) policy was developed at the onset of the process and enforced throughout. A stand-alone meeting was held for all panel members in December 2015. Teleconferences and electronic-based discussion among subgroups and among the entire committee served as an integral part of the development. Methods:The panel consisted of five sections: hemodynamics, infection, adjunctive therapies, metabolic, and ventilation. Population, intervention, comparison, and outcomes (PICO) questions were reviewed and updated as needed, and evidence profiles were generated. Each subgroup generated a list of questions, searched for best available evidence, and then followed the principles of the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system to assess the quality of evidence from high to very low, and to formulate recommendations as strong or weak, or best practice statement when applicable.

show abstract

Section: Combinaɵon Therapymentioning

confidence: 99%

Section: Combinaɵon Therapymentioning

confidence: 99%

Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Amikacin is a valuable therapeutic option for life-threatening aerobic Gram-negative organisms, especially Pseudomonas aeruginosa [8,9]. Optimum antibacterial activity is achieved when the peak serum concentration is at least eight to ten times the minimal inhibitory concentration of the causative Gram-negative pathogen [10,11].…”

Section: Continuous Renal Replacement Therapy (Crrt) Is Increasingly mentioning

confidence: 99%

Pharmacokinetics of a loading dose of amikacin in septic patients undergoing continuous renal replacement therapy

Taccone¹,

Backer²,

Laterre³

et al. 2011

International Journal of Antimicrobial Agents

View full text Add to dashboard Cite

“…84 The prescription of a combination therapy has been advocated to be effective in reducing mortality in patients presenting with severe sepsis or septic shock, [85][86] and when the infection is sustained by P. aeruginosa, 87 but results are controversial. 88 The major advantages of combination regimens have been found in infections caused by MDR and, specifically, carbapenemase-producing organisms. [89][90] For the treatment of BSIs sustained by KPC-producing Enterobacteriacae, which are the most common carbapenem-resistant nosocomial isolate, combination regimens including at least 2 active drugs have been associated with improved clinical outcomes and reduced mortality in comparison with the use of only one active drug, in particular when the combination includes a carbapenem.…”

Section: Gram Negative Bacteriamentioning

confidence: 99%

Bloodstream infections in the Intensive Care Unit

2016

View full text Add to dashboard Cite

Bloodstream infections (BSIs) represent a common complication among critically ill patients and a leading cause of morbidity and mortality. The prompt initiation of an effective antibiotic therapy is necessary in order to reduce mortality and to improve clinical outcomes. However, the choice of the empiric antibiotic regimen is often challenging, due to the worldwide spread of multi-drug resistant (MDR) organisms with reduced susceptibility to the available broad-spectrum antimicrobials. New therapeutic strategies are 5 to improve the effectiveness of antibiotic treatment while minimizing the risk of resistance selection.

show abstract

Beta lactam antibiotic monotherapy versus beta lactam-aminoglycoside antibiotic combination therapy for sepsis

Cited by 127 publications

References 111 publications

Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016

Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016

Pharmacokinetics of a loading dose of amikacin in septic patients undergoing continuous renal replacement therapy

Bloodstream infections in the Intensive Care Unit

Contact Info

Product

Resources

About